A growing body of research has identified the Epstein-Barr virus, best known as the cause of mononucleosis, as the strongest environmental risk factor for developing multiple sclerosis. The connection, built on military medical records spanning two decades and confirmed through molecular-level laboratory work, has shifted scientific understanding of MS from a disease of mysterious origin to one with a clear viral trigger. That shift is now driving new vaccine and antiviral strategies that could change how the disease is prevented and treated.
Military Records Reveal a 32-Fold Risk Increase
The most striking evidence linking EBV to MS comes from a prospective cohort analysis that drew on the U.S. Department of Defense serum repository, which holds blood samples from more than 10 million service members. Researchers obtained residual serum from 810 MS patients and 1,577 matched controls, tracking their infection status over years of active duty. As described in a long-term analysis of soldiers, the study identified 955 MS cases during military service and found that the risk of developing the disease rose approximately 32-fold after EBV seroconversion. No comparable increase appeared for other common viruses, including cytomegalovirus, underscoring that the association was specific to EBV rather than a general feature of viral exposure.
That 32-fold figure is not a modest statistical signal; it places EBV infection in a risk category comparable in strength to the relationship between smoking and lung cancer. The study also documented rises in neurofilament light chain levels, a biomarker of nerve damage, suggesting that neurological injury begins before clinical symptoms appear. In its summary of the findings, the U.S. biomedical agency emphasized that infection with EBV dramatically increased the odds of developing MS, supporting the virus as a leading cause of the disease rather than a bystander. Together, these data have convinced many researchers that EBV infection is a necessary precondition for most MS cases, even if it is not sufficient on its own.
How the Virus Tricks the Immune System
Epidemiological data alone cannot explain why a virus that infects the vast majority of adults causes MS in only a small fraction. The answer appears to lie in molecular mimicry, a process in which immune responses trained against viral proteins accidentally attack the body’s own tissue. A team led by immunologist William Robinson at Stanford identified cerebrospinal fluid antibodies from MS patients that bind both the EBV protein EBNA1 and a central nervous system protein called GlialCAM. Reporting from Stanford researchers highlighted crystal-structure evidence of this binding interaction and experiments showing that immunizing mice with EBNA1 could trigger cross-reactive immune responses targeting brain tissue, offering a direct mechanistic bridge from infection to autoimmunity.
Separate work has confirmed that EBNA1-directed antibodies also cross-react with another CNS protein, alpha-crystallin B (CRYAB). A case-control study of 713 MS patients and 722 controls found higher CRYAB epitope reactivity in the MS group, with the strongest disease risk appearing when high EBNA1 antibody responses co-occurred with CRYAB positivity. Blocking experiments confirmed that the same antibodies were responsible for both viral and self-directed binding. A follow-up using the Swedish EIMS cohort, which included 650 MS patients and 661 controls, replicated the elevated IgG reactivity to EBNA1 and multiple CNS mimic antigens, including GlialCAM, ANO2, and CRYAB. As summarized in a broader overview of EBV–MS links, these converging findings support a model in which EBV infection primes the immune system to generate antibodies that cannot distinguish viral targets from brain proteins, setting the stage for chronic inflammation and demyelination.
T Cells Add a Second Layer of Evidence
The antibody story is only half the picture. T cells, the immune system’s other major attack force, also appear to be misdirected by EBV in MS patients. A cerebrospinal fluid T-cell receptor sequencing study conducted at the earliest symptomatic stages of disease found that a substantial fraction of expanded T-cell clones in the spinal fluid responded to autologous EBV-infected B cells, with approximately 13% of CSF T-lymphocyte reads mapping to that specificity. This means that at the very onset of MS symptoms, a significant share of the immune cells flooding the nervous system are focused on EBV-infected targets rather than purely on self-antigens, providing a dynamic snapshot of the virus–immune interaction in real time.
A larger analysis of 1,317 samples from MS patients, healthy controls, and patients with other neuroinflammatory diseases found a broader MHC-I-restricted EBV-specific T-cell receptor repertoire unique to MS. That expanded repertoire did not appear in patients with neuromyelitis optica spectrum disorder, MOG antibody disease, or Susac’s syndrome, all of which affect the nervous system through different pathways. The study also reported that MS treatments modulated these EBV-specific repertoire signals, hinting that existing therapies may already be working in part by dampening the virus-driven immune response. Additional work from investigators in San Francisco, reported by a major West Coast medical center, has linked EBV-responsive immune cells to genetic pathways associated with MS susceptibility, suggesting that inherited risk and viral triggers converge on the same immune circuits.
From Cause to Cure: Vaccines and Antivirals
If EBV is the trigger, then preventing infection or suppressing the virus could theoretically prevent or slow MS. Moderna has developed an experimental mRNA vaccine that encodes several EBV surface proteins, aiming to block primary infection and reduce the risk of mononucleosis and downstream complications. According to a detailed report on early human testing, the first phase 1 trial of this vaccine platform began enrolling participants in early 2022, focusing on safety, immune responses, and dose selection. Although the study is not powered to detect effects on MS risk, it represents a critical proof of concept that EBV vaccination is feasible and immunogenic in people.
Beyond vaccines, researchers are exploring antiviral drugs and immune-based therapies that specifically target EBV-infected B cells and the T cells that respond to them. New findings highlighted by recent laboratory work indicate that CD8+ T cells recognizing distinct EBV proteins accumulate in the cerebrospinal fluid of people with MS, where they may both attempt to control the virus and inadvertently damage surrounding tissue. This has spurred interest in therapies that could recalibrate or deplete these virus-specific T cells, as well as in strategies that directly reduce the EBV reservoir within B cells, potentially using engineered cellular therapies or small-molecule inhibitors tailored to latent infection.
Implications for Patients and Future Research
For people living with MS today, the emerging EBV story does not immediately change standard treatment, but it does offer a clearer explanation of why the disease occurs and where new therapies might intervene. Clinicians are increasingly considering EBV status, antibody profiles, and T-cell signatures as part of research protocols, and future diagnostic tools may incorporate viral biomarkers to refine prognosis or tailor treatment. Educational initiatives from organizations such as the NIH science education program are beginning to translate these complex findings into accessible resources for students, patients, and families, helping them understand how a common childhood infection can, in rare cases, lead to a lifelong neurological illness.
For scientists, the EBV–MS connection is reshaping research priorities. Long-term cohort studies are now being designed to follow individuals from before EBV infection through potential MS onset, integrating genetics, environment, and detailed immune profiling. Laboratory groups are dissecting how specific viral proteins interact with human immune receptors and myelin components, with the goal of identifying “safe” targets for vaccines that avoid molecular mimicry. As these efforts progress, the hope is that MS will move from a condition managed after the fact to one that can be prevented or intercepted early in its course, transforming a once-enigmatic disease into a model of virus-driven autoimmunity that can be understood, predicted, and ultimately controlled.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
